EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting

Aman Sharma iD, Helen E Grimsley, Katharine Courtemanche, Simon N Powell

NAR Cancer · 2025

DOI: 10.1093/narcan/zcaf048 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift NAR Cancer, 2025. Verfasst von Aman Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY, NY 10065, United States. Hauptthemen laut MEDLINE: DNA-(Apurinic or Apyrimidinic Site) Lyase, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apurinic/apyrimidinic endonucleases - APE1 and APE2 are central to genome maintenance and the cellular DNA damage response, with expanding relevance in cancer biology. APE1 is the primary endonuclease in base excision repair and functions as a redox coactivator of transcription factors. In contrast, APE2 exhibits PCNA dependent 3′–5′ exonuclease and 3′-phosphodiesterase activities, contributing to microhomology-mediated end joining, ATR-Chk1 activation, and immunoglobulin diversification. Both enzymes are often deregulated in cancer: APE1 is frequently overexpressed, drives tumor progression and chemoresistance, while APE2 is similarly upregulated in multiple malignancies. APE1 can be targeted by redox-specific or endonuclease inhibitors, with early clinical evidence of biological activity and tolerability. Although APE2-specific inhibitors remain in early development, emerging synthetic lethality data and preclinical studies highlight APE2 as a novel clinical target in breast cancer type 1/2 susceptibility (BRCA)-mutated cancers. This review discusses the structural and functional roles of APE1 and APE2, their contributions to cancer biology and therapeutics, recent advances in inhibitor development, and future strategies for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-(Apurinic or Apyrimidinic Site) LyaseNeoplasmsHumansDNA RepairMolecular Targeted TherapyAnimalsDNA DamageAntineoplastic AgentsEndonucleasesMultifunctional Enzymes

Substanzen

DNA-(Apurinic or Apyrimidinic Site) LyaseAPEX1 protein, humanAPEX2 protein, humanAntineoplastic AgentsEndonucleasesMultifunctional Enzymes

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY, NY 10065, United States.

ORCID-Profile: Aman Sharma

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Sharma, A., Grimsley, H. E., Courtemanche, K., & Powell, S. N. (2025). Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting. NAR Cancer. https://doi.org/10.1093/narcan/zcaf048

Vancouver

Sharma A, Grimsley HE, Courtemanche K, Powell SN. Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting. NAR Cancer. 2025. doi:10.1093/narcan/zcaf048

BibTeX
@article{Sharma2025,
  author = {Sharma, Aman and Grimsley, Helen E and Courtemanche, Katharine and Powell, Simon N},
  title = {Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting},
  journal = {NAR Cancer},
  year = {2025},
  doi = {10.1093/narcan/zcaf048}
}
Kostenlos starten →